Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy

Core Insights - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is identified as one of the best growth stocks under $25, with a price target raised from $22 to $24 by Bank of America Securities while maintaining a Buy rating [1] Financial Performance - Teva's management anticipates full-year revenue between $16.8 billion and $17.2 billion, indicating a year-over-year increase of 2% to 4%, which aligns with the consensus estimate of $16.901 billion [3] Market Trends - The analyst from Bank of America previewed EPS estimates for commercial-stage biotech companies, indicating no major surprises expected for Q3 in the sector based on pricing volume trends for key drugs [2]